Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,985 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A, Nakamura M, Ojima H, Kagawa Y, Matsuhashi N, Okuda H, Asayama M, Yuasa Y, Shimada Y, Manaka D, Watanabe J, Oba K, Yoshino T, Yoshida K, Maehara Y. Takahashi T, et al. Among authors: maehara y. ESMO Open. 2021 Apr;6(2):100093. doi: 10.1016/j.esmoop.2021.100093. Epub 2021 Mar 19. ESMO Open. 2021. PMID: 33744811 Free PMC article. Clinical Trial.
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5).
Tanaka Y, Takeuchi H, Nakashima Y, Nagano H, Ueno T, Tomizuka K, Morita S, Emi Y, Hamai Y, Hihara J, Saeki H, Oki E, Kunisaki C, Otsuji E, Baba H, Matsubara H, Maehara Y, Kitagawa Y, Yoshida K. Tanaka Y, et al. Among authors: maehara y. ESMO Open. 2021 Oct;6(5):100277. doi: 10.1016/j.esmoop.2021.100277. Epub 2021 Oct 6. ESMO Open. 2021. PMID: 34626918 Free PMC article. Clinical Trial.
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
Yamazaki K, Yamanaka T, Shiozawa M, Manaka D, Kotaka M, Gamoh M, Shiomi A, Makiyama A, Munemoto Y, Rikiyama T, Fukunaga M, Ueki T, Shitara K, Shinkai H, Tanida N, Oki E, Sunami E, Ohtsu A, Maehara Y, Yoshino T. Yamazaki K, et al. Among authors: maehara y. Ann Oncol. 2021 Jan;32(1):77-84. doi: 10.1016/j.annonc.2020.10.480. Epub 2020 Oct 26. Ann Oncol. 2021. PMID: 33121997 Free article. Clinical Trial.
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E, Murata A, Yoshida K, Maeda K, Ikejiri K, Munemoto Y, Sasaki K, Matsuda C, Kotake M, Suenaga T, Matsuda H, Emi Y, Kakeji Y, Baba H, Hamada C, Saji S, Maehara Y. Oki E, et al. Among authors: maehara y. Ann Oncol. 2016 Jul;27(7):1266-72. doi: 10.1093/annonc/mdw162. Epub 2016 Apr 7. Ann Oncol. 2016. PMID: 27056996 Free PMC article. Clinical Trial.
Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
Takatsuki M, Tokunaga S, Uchida S, Sakoda M, Shirabe K, Beppu T, Emi Y, Oki E, Ueno S, Eguchi S, Akagi Y, Ogata Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Takatsuki M, et al. Among authors: maehara y. Eur J Surg Oncol. 2016 Feb;42(2):184-9. doi: 10.1016/j.ejso.2015.11.007. Epub 2015 Nov 22. Eur J Surg Oncol. 2016. PMID: 26683263 Free article. Clinical Trial.
Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K, Emi Y, Iyama KI, Beppu T, Ogata Y, Kakeji Y, Samura H, Oki E, Akagi Y, Maehara Y, Baba H; Kyusyu Study Group of Clinical Cancer (KSCC) ancillary study. Imai K, et al. Among authors: maehara y. Eur J Surg Oncol. 2014 May;40(5):559-566. doi: 10.1016/j.ejso.2013.12.009. Epub 2013 Dec 20. Eur J Surg Oncol. 2014. PMID: 24388740
1,985 results